---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-123033"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:48:43.100424+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kyverna prices $100M public offering of 13.3M shares at $7.50 per share

## Summary
- Offering of 13,333,333 shares of common stock at $7.50/share; gross proceeds ~$100M.
- Underwriters granted a 30-day option to purchase up to 1,999,999 additional shares at $7.50/share less discounts.
- Net proceeds for general corporate purposes, including R&D, capex, working capital.
- Expected closing on or about December 18, 2025; directors, officers, affiliates subject to lock-up through January 31, 2026.
- Joint book-running managers: J.P. Morgan, Leerink Partners, Morgan Stanley, Wells Fargo Securities.

## SEC filing metadata
- accession: 0001213900-25-123033
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000121390025123033/0001213900-25-123033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000121390025123033/ea0270041-8k_kyverna.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-123033
- JSON: https://secwatch.observer/filing/0001213900-25-123033.json
- Plain text: https://secwatch.observer/filing/0001213900-25-123033.txt

## Key facts
- Material Agreements
  Kyverna Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC valued at approximately $100 million (effective 2025-12-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC
  - Value: approximately $100 million
  - Effective: 2025-12-17
  source text: On December 17, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC as the representatives (the “Representatives”) of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of an aggregate of 13,333,333 shares of common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000121390025123033/0001213900-25-123033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.